LivaNova (LIVN) Draws Fair Value Focus, Is The 12% Upside Still There?

LivaNova (LIVN) has caught investor attention after recent trading left the stock around $78.50, with returns mixed over the past month and past 3 months but stronger over the year and multi year periods.

Recent trading tells a split story for LivaNova. In the short term, the share price return over the past 30 and 90 days has slipped slightly. However, a year-to-date share price gain near 30% and a 1 year total shareholder return of 45.67% point to momentum that has been building rather than fading as investors reassess both growth prospects and risk around the current US$78.50 level.

Compare LivaNova's recent momentum with a hand picked group of resilient healthcare and medtech names using the 32 resilient stocks with low risk scores to see which ones also pair solid fundamentals with lower risk profiles.

LivaNova now trades near US$78.50 after a strong 1 year run, so the key question is whether that move already reflects fair value or still leaves a meaningful margin of safety.

Most Popular Narrative: 12% Undervalued

LivaNova's most followed valuation story points to a fair value of $89.10, which sits above the recent $78.50 close and frames the current debate around upside versus already priced-in expectations.

The analysts have a consensus price target of $89.1 for LivaNova based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $100.0, and the most bearish reporting a price target of just $75.0.

See why 5 investors see LivaNova as 12% undervalued.

Result: Fair Value of $89.10 (UNDERVALUED)

Still, the bullish fair value story for LivaNova can be knocked off course if reimbursement tightens or if higher R&D spend fails to translate into approvals.

Find out about the key risks to this LivaNova narrative.

Next Steps

Mixed signals on LivaNova can either unsettle you or encourage you to look more closely at the facts that matter most. Consider the situation while sentiment is still divided and weigh both sides of the story by reviewing the 4 key rewards and 1 important warning sign.

Looking for more LivaNova style investment ideas?

If you stop with LivaNova, you miss a wider opportunity set. Use the Simply Wall Street Screener to spot other stocks that might suit your plan.

• Target stocks that mix quality with a potential discount by running the 33 high quality undervalued stocks.
• Prioritise resilient balance sheets and cleaner financial footing through the list of solid balance sheet and fundamentals (25 results).
• Hunt for quieter opportunities that the market has not crowded yet by scanning the 20 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com